ESMO CONGRESS 2021Конгресс
Доклады:
-
2021
Efficacy and toxicity of biosimilar and original bevacizumab in the second-line treatment of metastatic colon cancer in routine clinical practice: Results of an observational multicenter study
(Стендовый)
-
Авторы:
Fedyanin Mikhail,
Moiseenko F.,
Lyadova M.,
Vorobeva E.,
Gladkov O.,
Petkau V.,
Fateeva A.,
Kuzmina E.,
Novikova O.,
Chubenko,
Viacheslav,
Abduloeva N.,
Kudryavtsev A.,
Ignatova E.,
Shakirov R.,
Pardabekova O.,
Kindyalova L.,
Pelikh S.,
Tjulandin S.,
Tryakin A.
-
2021
Efficacy and toxicity of biosimilar and original bevacizumab in the second-line treatment of metastatic colon cancer in routine clinical practice: Results of an observational multicenter study
(Стендовый)
-
Авторы:
Fedyanin Mikhail,
Moiseenko F.,
Lyadova M.,
Vorobeva E.,
Gladkov O.,
Petkau V.,
Fateeva A.,
Kuzmina E.,
Novikova O.,
Chubenko,
Viacheslav,
Abduloeva N.,
Kudryavtsev A.,
Ignatova E.,
Shakirov R.,
Pardabekova O.,
Kindyalova L.,
Pelikh S.,
Tjulandin S.,
Tryakin A.
-
2021
Efficacy and toxicity of biosimilar and original bevacizumab in the second-line treatment of metastatic colon cancer in routine clinical practice: Results of an observational multicenter study
(Стендовый)
-
Авторы:
Fedyanin Mikhail,
Moiseenko F.,
Lyadova M.,
Vorobeva E.,
Gladkov O.,
Petkau V.,
Fateeva A.,
Kuzmina E.,
Novikova O.,
Chubenko,
Viacheslav,
Abduloeva N.,
Kudryavtsev A.,
Ignatova E.,
Shakirov R.,
Pardabekova O.,
Kindyalova L.,
Pelikh S.,
Tjulandin S.,
Tryakin A.
-
2021
Efficacy and toxicity of biosimilar and original bevacizumab in the second-line treatment of metastatic colon cancer in routine clinical practice: Results of an observational multicenter study
(Стендовый)
-
Авторы:
Fedyanin Mikhail,
Moiseenko F.,
Lyadova M.,
Vorobeva E.,
Gladkov O.,
Petkau V.,
Fateeva A.,
Kuzmina E.,
Novikova O.,
Chubenko,
Viacheslav,
Abduloeva N.,
Kudryavtsev A.,
Ignatova E.,
Shakirov R.,
Pardabekova O.,
Kindyalova L.,
Pelikh S.,
Tjulandin S.,
Tryakin A.